UBE2W is a ubiquitin-conjugating enzyme (E2) that catalyzes monoubiquitination of substrate proteins, with a distinctive mechanism of modifying the N-terminal amino group rather than lysine residues 1. The enzyme accepts ubiquitin from E1 complexes and attaches it to various substrates including ATXN3, MAPT/TAU, and STUB1/CHIP by recognizing backbone atoms of disordered N-termini. UBE2W plays specialized roles in DNA damage responses: it associates with the FANCL E3 ligase to catalyze monoubiquitination of FANCD2 following UV irradiation, a critical step in Fanconi anemia pathway activation 2. The enzyme also mediates degradation of misfolded chaperone substrates by monoubiquitinating STUB1/CHIP, which restricts ubiquitin chain length and coordinates protein quality control. Recent evidence suggests UBE2W modulates alpha-synuclein degradation through a proteasome-dependent mechanism dependent on amino-terminal acetylation 3. Clinically, UBE2W down-regulation correlates with hypospermatogenesis and male infertility, with reduced expression associated with activation of apoptotic pathways in spermatogenic cells 4. In breast cancer, high UBE2W expression correlates with mismatch repair gene mutations and may promote tumor immunosuppression and endocrine therapy resistance 5. UBE2W represents a potential therapeutic target for managing protein quality control defects and cancer-associated pathways.